Breast Cancer | Specialty

Avelumab Effective in PD-L1-Positive Metastatic Breast Cancer

December 9th 2015

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Adjuvant Chemotherapy May Not Improve Outcomes in Luminal A Breast Cancer

December 9th 2015

Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.

Denosumab Demonstrates Survival Benefit in Postmenopausal Women

December 9th 2015

A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.

Adjuvant Capecitabine Improves Survival in HER2-Negative Breast Cancer

December 9th 2015

Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.

Short Course Radiation Treatment for Breast Cancer

December 9th 2015

Active research and advancements in the field focuses on lessening the burden of radiation treatment while still maintaining acceptable cosmetic outcomes for patients with breast cancer.

Hudis on ExteNET, APHINITY, and What's Next for Adjuvant HER2+ Breast Cancer

December 4th 2015

Clifford Hudis, MD, discusses the evolving adjuvant therapy options in HER2-positive breast cancer.

Dr. Nimmi Kapoor on Multigene Panel Testing for Hereditary Breast Cancer

December 3rd 2015

Nimmi Kapoor, MD, Breast and Thyroid Surgical Oncologist at Breastlink, discusses the benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer.

Dr. Kuske on APBI Via Multicatheter Interstitial Brachytherapy

November 26th 2015

Robert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses the analysis of the Pooled Registry of Multicatheter Interstitial Sites Experience, which examined the safety of accelerated partial breast irradiation via multicatheter interstitial brachytherapy.

How Genetic Testing Impacts Breast Cancer Treatment Decisions

November 10th 2015

As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions.

Dr. Borgen on Surgical Versus Medical Treatment of Breast Cancer

November 5th 2015

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

Dr. Vicini on Accelerated Partial Breast Irradiation in Low-Risk Breast Cancer

October 29th 2015

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, discusses a European study that examined the efficacy of accelerated partial breast irradiation versus conventional whole breast irradiation in patients with low-risk breast cancer.

Accelerated Partial Breast Irradiation Demonstrates Efficacy in Low-Risk Breast Cancer

October 25th 2015

Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.

American Cancer Society Updates Breast Cancer Screening Guideline

October 21st 2015

The American Cancer Society now recommends that women at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45.

Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More

October 16th 2015

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Multigene Panel May Allow Some HR+/HER2- Breast Cancer Patients to Avoid Chemotherapy

October 13th 2015

Patients with hormone receptor (HR)–positive, HER2-negative breast cancer who have a favorable gene-expression profile may be able to avert chemotherapy and receive endocrine treatment alone.

Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

October 9th 2015

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Dr. Montes on the Relationship of MRI Imaging Characteristics With Race

October 8th 2015

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.

FDA Grants Abemaciclib Breakthrough Status for Refractory Breast Cancer

October 8th 2015

The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer.

Dr. Lambertini on Preserving Ovarian Function and Fertility During Chemotherapy Treatment

October 6th 2015

Matteo Lambertini, MD, Department of Medical Oncology, U.O. Oncologia Medica A, Hospital San Martino, Genova, Italy, discusses the use of luteinizing hormone-releasing hormone agonists (LHRHa) during chemotherapy to preserve ovarian function and fertility in patients with breast cancer.